AttendMe Owl Logo
AttendMe
Evidence Evolution
Evidence Evolution
Landmark TrialRCTRandomized Controlled Trial

Immunosuppressive therapy in lupus nephritis: The Euro‐Lupus Nephritis Trial, a randomized trial of low‐dose versus high‐dose intravenous cyclophosphamide

Arthritis & Rheumatism2002

Frédéric Houssiau Carlos Vasconcelos David D’Cruz Gian Domenico Sebastiani Enrique de Ramón Garrido Maria Giovanna Danieli Daniel Abramovicz Daniël Blockmans Alessandro Mathieu Haner Di̇reskeneli̇ Mauro Galeazzi Ahmet Gül Yair Levy P Petera Rajko Popović Radmila Petrović Renato Alberto Sinico Roberto Cattaneo Josep Font Geneviève Depresseux Jean‐Pierre Cosyns Ricard Cervera

PMID: 12209517View on PubMedDOI

Abstract

The data from the ELNT indicate that in European SLE patients with proliferative lupus nephritis, a remission-inducing regimen of low-dose IV CYC (cumulative dose 3 gm) followed by AZA achieves clinical results comparable to those obtained with a high-dose regimen.

Specialty

Rheumatology

Featured in Evidence Evolutions